齐拉西酮治疗精神分裂症疗效及不良反应的相关因素分析

doi:10.3969/j.issn.1006-7795.2016.02.011

首都医科大学学报 ›› 2016, Vol. 37 ›› Issue (2): 164-167.doi: 10.3969/j.issn.1006-7795.2016.02.011

齐拉西酮治疗精神分裂症疗效及不良反应的相关因素分析

朱虹¹, 贾竑晓¹, 阎爱国², 职利花¹

1. 首都医科大学附属北京安定医院中西医结合研究室北京重大脑疾病研究院精神分裂症研究所精神疾病诊断与治疗北京市重点实验室, 北京 100088;
2. 北京平谷区精神病医院4区, 北京 101201

收稿日期:2016-01-20 出版日期:2016-04-21 发布日期:2016-04-14
通讯作者: 贾竑晓 E-mail:jhxlj@vip.163.com
基金资助:
北京市自然科学基金(7152069),北京市科委首都临床特色应用研究专项(Z151100004015061)

Predictive factors for efficacy and adverse reactions of ziprasidone in schizophrenia patients

Zhu Hong¹, Jia Hongxiao¹, Yan Aiguo², Zhi Lihua¹

1. Research office of Integrated Traditional Chinese and Western Medicine, Beijing Anding Hospital, Capital Medical University, Center of Schizophrenia, Beijing Institute for Brain Disorders, Beijing Key Laboratory for Mental Disorders, Beijing 100088, China;
2. Ward No. 4 of Beijing Pinggu Psychiatric Hospital, Beijing 101201, China

Received:2016-01-20 Online:2016-04-21 Published:2016-04-14
Supported by:
This study was supported by Natural Science Foundation of Beijing (7152069), Clinical Characteristics Program of Beijing Municipal Science and Technology Commission (Z151100004015061).

摘要/Abstract

摘要： 目的分析70例经齐拉西酮治疗的精神分裂症患者疗效及锥体外系反应的相关因素。方法对70例经齐拉西酮治疗的精神分裂症患者的疗效及锥体外系反应的相关因素进行线性回归分析。结果疾病明显发作次数少是齐拉西酮疗效好的预测因素(β=-0.496, P=0.000);既往有无明显急性肌张力障碍和帕金森综合征、以阳性症状为主及疾病明显发作次数是有明显急性肌张力障碍和类帕金森综合征的预测因素(β分别为-0.634、0.332、-0.181,P分别为0.000、0.000、0.054);既往有明显静坐不能、疾病明显发作次数是明显静坐不能的预测因素(β分别为0.633、0.136, P分别为0.000、0.034)。阴性症状、病程长是齐拉西酮治疗有静坐不能的保护性因素(β分别为-0.310、-0.181,P分别为0.000、0.024)。结论疾病明显发作次数少的精神分裂症患者采用齐拉西酮治疗的疗效较好;既往有明显锥体外系反应史者、疾病明显发作次数少者应用齐拉西酮易发生明显锥体外系反应;以阴性症状为主、病程长的精神分裂症患者应用齐拉西酮不易发生静坐不能;以阳性症状为主者易发生急性肌张力障碍和类帕金森综合征。

关键词: 精神分裂症, 齐拉西酮, 疗效, 锥体外系反应, 预测因素

Abstract: Objective To analyze factors related to efficacy of ziprasidone and extrapyramidal symptom (EPS) in 70 schizophrenia patients treated with ziprasidone. Methods Multi linear Logistic regression was used to analyze factors related to efficacy of the treatment and extrapyramidal symptom in 70 schizophrenia patients treated with ziprasidone.Results Significant episodes of the disease were the predictor for the good effect of ziprasidone(β=-0.496, P=0.000). Previous history with acute dysmyotonia and Parkinson syndrome, prominent positive symptom, were the predictor for acute dysmyotonia and Parkinson syndrome(β=-0.634, 0.332 respectively, P=0.000 for both). Previous history of akathisia, prominent positive symptom, and relapse time of disease were the predictor for akathisia(β=0.633, 0.136 respectively, P=0.000, 0.034 respectively), prominent negative symptom and duration of disease were the protective factors for akathisia(β=-0.310, -0.181 respectively, P=0.000, 0.024 respectively).Conclusion Schizophrenia patients with few relapses of disease will demonstrate good therapeutic effect when treated with ziprasidone. Schizophrenia patients with previous history of extrapyramidal symptom, or with fewer relapses of disease may show higher occurrence of EPS; patients with prominent negative symptom, long duration of disease may predict lower occurrence of akathisia. Patients with prominent positive symptom may predict higher occurrence of acute dysmyotonia and Parkinson syndrome.

Key words: schizophrenia, ziprasidone, effect, extrapyramidal symptom, predictive factors

中图分类号:

R749.05

朱虹, 贾竑晓, 阎爱国, 职利花. 齐拉西酮治疗精神分裂症疗效及不良反应的相关因素分析[J]. 首都医科大学学报, 2016, 37(2): 164-167.

Zhu Hong, Jia Hongxiao, Yan Aiguo, Zhi Lihua. Predictive factors for efficacy and adverse reactions of ziprasidone in schizophrenia patients[J]. Journal of Capital Medical University, 2016, 37(2): 164-167.

参考文献

[1] American Psychiatric Association. Diagnostic and statistic manual of mental disorders[M].Washington D C:American Psychiatric Press, Inc., 2000.
[2] 易正辉,卢卫红,朱丽萍,等.第二代抗精神病药的进一步研究(三)利培酮早期反应预测后期疗效的研究[J].临床精神医学杂志,2004, 14(1):37-38.
[3] 卢晓星.影响精神分裂症患者抗精神病药物治疗效果的因素分析[J].重庆医学,2013,42(21):2473-2475.
[4] Lewis D A, Lieberman J A. Catching up on schizophrenia:natural history and neurobiology[J]. Neuron, 2000, 28(2):325-334.
[5] Keefe R S, McEvoy J P. Negative symptom and cognitive deficit treatment response in schizophrenia[M]. Washington DC:American Psychiatric Press, Inc., 2001, 163-175.
[6] Takeuchi H, Suzuki T, Bies R R,et al. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia:An analysis of the CATIE data[J]. Schizophr Res, 2013,150(2-3):373-379.
[7] Blaisdell G D. Akathisia:a comprehensive review and treatment summary[J]. Pharmacopsychiatry, 1994, 27(4):139-146.
[8] Lechin F, van der Dijs B.Noradrenergic hypothesis of schizophrenia[J]. Prog Neuro Psychopharmacol & Biological Psychiatry, 2005, 29(5):777-778.
[9] Stahl S M, Shayegan D K.The psychopharmacology of ziprasidone:receptor-binding properties and real-world psychiatric practice[J]. J Clin Psychiatry, 2003, 64 (Suppl 19):6-12.
[10] Comai S, Tau M, Pavlovic Z,et al. The psychopharmacology of aggressive behavior:a translational approach:part 2:clinical studies using atypical antipsychotics, anticonvulsants, and lithium[J]. J Clin Psychopharmacol, 2012,32(2):237-260.
[11] Olié J P, Spina E, Murray S,et al.Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia:results of a 12-week, double-blind study[J]. Int Clin Psychopharmacol, 2006, 21(3):143-151.
[12] Kuepper R, Skinbjerg M, Abi-Dargham A. The dopamine dysfunction in schizophrenia revisited:new insights into topography and course[J]. Handb Exp Pharmacol, 2012(212):1-26.

[1]	罗炯, 孙丛丛, 潘伟刚, 王丹, 史晓宁, 王茜, 金文青, 梁立荣, 杨春林, 马辛, 任艳萍. 经颅交流电刺激联合抗抑郁药对抑郁发作的疗效及安全性[J]. 首都医科大学学报, 2022, 43(2): 244-248.
[2]	廉思源, 吴涵, 韩金祥, 肖存利, 任艳萍, 金文青, 王雯, 马辛. 影响精神分裂症自我报告康复效果的因素[J]. 首都医科大学学报, 2022, 43(2): 233-238.
[3]	任艳萍, 张俊岩, 吴涵, 罗炯, 杨春林, 马辛, 姜玮. 磁惊厥治疗与无抽搐电痉挛治疗抑郁发作的早期疗效及对认知功能的影响[J]. 首都医科大学学报, 2022, 43(2): 239-243.
[4]	李莉, 刘超猛, 任艳萍, 杨春林, 马辛. 改良电休克治疗首发精神分裂症的研究进展[J]. 首都医科大学学报, 2022, 43(2): 249-253.
[5]	郭城伟, 周娇娇, 冯媛, 杨蕴萍. 精神分裂症患者与正常人自尊水平的对照研究[J]. 首都医科大学学报, 2022, 43(2): 294-298.
[6]	朱平, 禹环, 符丽梅, 廖欣, 熊暮珺, 雷阿明, 祝平安, 梁欣荃. 脐血移植治疗难治复发急性白血病的临床分析[J]. 首都医科大学学报, 2021, 42(6): 1041-1045.
[7]	陈溪, 马登磊, 李林. 淫羊藿苷对cuprizone诱导精神分裂症样小鼠模型行为学变化、髓鞘脱失及神经炎性反应的影响[J]. 首都医科大学学报, 2021, 42(5): 761-767.
[8]	宁艳哲, 朱虹, 宋楠, 郑思思, 李自艳, 李佳佳, 马睿, 贾竑晓. 石珍安神颗粒改善精神分裂症前驱期患者认知损害的临床观察[J]. 首都医科大学学报, 2021, 42(3): 404-407.
[9]	仪玉伟, 闫芳, 靳玉宏, 肖存利. 精神分裂症住院患者危险行为的影响因素分析[J]. 首都医科大学学报, 2021, 42(2): 323-327.
[10]	沙莎, 赵希希, 韩传亮, 彭兴, 张培, 董雯, 尹晶晶, 王长明. 精神分裂症静息态下alpha活动和认知水平的相关性[J]. 首都医科大学学报, 2021, 42(1): 117-124.
[11]	张颖, 王若梅, 李刚. 稳定期精神分裂症患者认知功能、情绪管理水平及其影响因素分析[J]. 首都医科大学学报, 2021, 42(1): 143-147.
[12]	鄢丹. 临床生物特征谱学:中药质量与临床合理用药评价——鄢丹教授[J]. 首都医科大学学报, 2020, 41(5): 773-777.
[13]	余英, 高峰, 张杰. 反流性食管炎治疗效果与食管下段菌群构成变化的关系研究[J]. 首都医科大学学报, 2020, 41(2): 243-248.
[14]	刘鑫垚, 马超, 贾竑晓. 精神分裂症认知损害动物模型的研究现状[J]. 首都医科大学学报, 2020, 41(1): 50-54.
[15]	马超, 贺毅, 孙作厘, 刘鑫垚, 冯正田, 陈沛, 宁艳哲, 朱虹, 尹冬青, 贾竑晓. 基于16S rRNA技术分析石珍安神汤对脱髓鞘小鼠肠道菌群多样性的影响[J]. 首都医科大学学报, 2020, 41(1): 64-70.

齐拉西酮治疗精神分裂症疗效及不良反应的相关因素分析

Predictive factors for efficacy and adverse reactions of ziprasidone in schizophrenia patients

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价